Trials / Completed
CompletedNCT01197066
Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis
A Phase Ⅲ Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab Pegol | Certolizumab Pegol 200mg |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2010-09-09
- Last updated
- 2022-06-10
Source: ClinicalTrials.gov record NCT01197066. Inclusion in this directory is not an endorsement.